1. Home
  2. AUID vs NEUP Comparison

AUID vs NEUP Comparison

Compare AUID & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo authID Inc.

AUID

authID Inc.

HOLD

Current Price

$1.82

Market Cap

25.8M

Sector

Technology

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.41

Market Cap

23.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUID
NEUP
Founded
2009
1996
Country
United States
United States
Employees
N/A
8
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
25.8M
23.0M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
AUID
NEUP
Price
$1.82
$4.41
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
387.9K
26.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
60.00
N/A
EPS
N/A
N/A
Revenue
$886,485.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
365.86
N/A
52 Week Low
$0.84
$3.65
52 Week High
$9.44
$21.31

Technical Indicators

Market Signals
Indicator
AUID
NEUP
Relative Strength Index (RSI) 59.10 59.15
Support Level $1.19 $3.99
Resistance Level $1.94 $4.56
Average True Range (ATR) 0.18 0.18
MACD 0.00 0.02
Stochastic Oscillator 98.35 83.93

Price Performance

Historical Comparison
AUID
NEUP

About AUID authID Inc.

AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: